Natural cholera infection-derived immunity in an endemic setting

Journal of Infectious Diseases

Volumn 204, Issue 6, 2011, Pages 912-918

  Ali, Mohammad ^a   Emch, Michael ^b   Park, Jin Kyung ^a   Yunus, Mohammad ^c   Clemens, John ^a  

^a International Vaccine Institute   (South Korea)

^b UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL   (United States)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; LIVE CHOLERA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BACTERIAL STRAIN; BANGLADESH; CHILD; CHOLERA; COHORT ANALYSIS; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HUMAN; INFECTION RISK; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTECTION; RISK REDUCTION; SCHOOL CHILD; SEROTYPE; VIBRIO CHOLERAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BANGLADESH; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; ENDEMIC DISEASES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SEROTYPING; VIBRIO CHOLERAE; YOUNG ADULT;

EID: 80052190201     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir416     Document Type: Article

References (27)

1. Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev Vaccines 2006; 5:483-94. (Pubitemid 44627880)
2. Albert MJ, Siddique AK, Islam MS, et al. Large outbreak of clinical cholera due to Vibrio cholerae non-1 in Bangladesh. Lancet 1993; 341:704. (Pubitemid 23083298)
3. Comstock LE, Maneval D Jr, Panigrahi P, et al. The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun 1995; 63:317-23.
4. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; 2:467-70.
5. Tacket CO, Kotloff KL, Losonsky G, et al. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am J Trop Med Hyg 1997; 56:533-7.
6. Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine 1993; 11:207-12. (Pubitemid 23031509)
7. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbial Rev 1983; 47:510-50. (Pubitemid 14210910)
8. Glass RI, Becker S, Huq MI, et al. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol 1982; 111:959-70. (Pubitemid 13209569)
9. Clemens JD, Van Loon FPL, Sack DA, et al. Biotype as a determinant of the natural immunizing effect of V. cholerae 01. Lancet 1991; 337:883-4.
10. Woodward W. Cholera reinfection in man. J Infect Dis 1971; 123:61-6.
11. Emch M, Ali M, Root ED, Yunus M. Spatial and environmental connectivity analysis in a cholera vaccine trial. Soc Sci Med 2009; 68:631-7.
12. Koenig MA, Fauveau V, Chowdhury AI, et al. Maternal mortality in Matlab, Bangladesh: 1976-85. Stud Fam Plann 1988; 19:69-80.
13. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; ii:124-17.
14. Barua D. Laboratory diagnosis of cholera. In: Barua D, Burrows W eds. Cholera. Philadelphia, PA: Saunders, 1974; 85-128.
15. Gangarosa EJ, De Witt WE, Huq I, Zarifi A. Laboratory methods in cholera: Isolation of Vibrio cholerae (El Tor and classical) on TCBS medium in minimally equipped laboratories. Trans R Soc Trop Med Hyg 1968; 62:693-9.
16. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York: Springer-Verlag, 1997.
17. Reid N, Crepeau H. Influence functions for proportional hazards regression. Biometrika 1985; 72:1-9.
18. Lin D, Wei L. The robust inference for the proportional hazards model. J Am Stat Assoc 1989; 84:1074-8.
19. Tacket CO, Losonsky G, Nataro J, et al. Initial clinical studies of CVD112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against an experimental challenge. J Infect Dis 1995; 172:883-6.
20. Albert MJ, Alam K, Ansaruzzaman M, Qadri F, Sack RB. Lack of crossprotection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. J Infect Dis 1994; 169:709-10. (Pubitemid 24063035)
21. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. Lack of crossprotection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with Vibrio cholerae O139 Bengal. J Infect Dis 1994; 169:709-10(Letter). (Pubitemid 24063035)
22. Mosely WH, McCormick W, Fahimuddin M, et al. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. Bull WHO 1969; 40:177-85.
23. Watanabe Y. Antibacterial immunity in cholera. In: Barua D, Burrows W eds eds. Cholera. Philadelphia, PA: WB Saunders, 1974; 283-306.
24. Longini I, Yunus M, Zaman K, Siddique A, Sack RB, Nizam A. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis 2002; 186:246-51. (Pubitemid 34765514)
25. Hisatsune K, Kondo S, Isshiki Y, Iguchi T, Haishima Y. Occurrence of 2-O-methyl-N-(3-deoxy-l-glycero-tetronyl)-d-perosamine (4-amino-4, 6-dideoxy-d-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. Biochem Biophys Res Commun 1993; 190:302-7.
26. Ito T, Higuchi T, Hirobe M, Hiramatsu K, Yokota T. Identification of a novel sugar, 4-amino-4,6-dideoxy-2-Omethylmannose in the lipopolysaccharide of Vibrio cholerae O1 serotype Ogawa. Carbohydr Res 1994; 256:113-28. (Pubitemid 24103141)
27. Wang J, Villeneuve S, Zhang J, et al. On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O1, serotypes Ogawa and Inaba. J Biol Chem 1998; 273:2777-83.